NovoCure Dirección
Dirección controles de criterios 4/4
El CEO de NovoCure's es Asaf Danziger , nombrado en Jan 2002, tiene una permanencia de 22.25 años. compensación anual total es $2.28M, compuesta por 36.4% salario y 63.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.013% de las acciones de la empresa, por valor de $168.64K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 6.4 años, respectivamente.
Información clave
Asaf Danziger
Chief Executive Officer (CEO)
US$1.5m
Compensación total
| Porcentaje del salario del CEO | 49.7% |
| Permanencia del CEO | 22.3yrs |
| Participación del CEO | 0.01% |
| Permanencia media de la dirección | 3.7yrs |
| Promedio de permanencia en la Junta Directiva | 6.5yrs |
Actualizaciones recientes de la dirección
Recent updates
NovoCure Limited Q1 Earnings: Core Business Accelerating
May 03NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08
NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)
Apr 24Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching
Feb 10Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Jan 16NovoCure: See Past Market Myopia And Buy The Dip
Sep 27Novocure creates new CNS focused franchise to renew growth in brain cancer business
Sep 21Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Sep 09NovoCure: Does The Reward Outweigh The Risk? I Believe So
Sep 09NovoCure Q2 2022 Earnings Preview
Jul 27Is NovoCure (NASDAQ:NVCR) Using Too Much Debt?
May 28NovoCure: A Stalwart With More Upsides
May 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$193m |
| Dec 31 2023 | US$2m | US$756k | -US$207m |
| Sep 30 2023 | n/a | n/a | -US$197m |
| Jun 30 2023 | n/a | n/a | -US$174m |
| Mar 31 2023 | n/a | n/a | -US$141m |
| Dec 31 2022 | US$2m | US$831k | -US$93m |
| Sep 30 2022 | n/a | n/a | -US$82m |
| Jun 30 2022 | n/a | n/a | -US$68m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$1m | US$876k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$27m |
| Jun 30 2021 | n/a | n/a | -US$5m |
| Mar 31 2021 | n/a | n/a | US$12m |
| Dec 31 2020 | US$9m | US$782k | US$20m |
| Sep 30 2020 | n/a | n/a | US$19m |
| Jun 30 2020 | n/a | n/a | US$12m |
| Mar 31 2020 | n/a | n/a | US$9m |
| Dec 31 2019 | US$7m | US$702k | -US$7m |
| Sep 30 2019 | n/a | n/a | -US$27m |
| Jun 30 2019 | n/a | n/a | -US$41m |
| Mar 31 2019 | n/a | n/a | -US$55m |
| Dec 31 2018 | US$5m | US$693k | -US$64m |
| Sep 30 2018 | n/a | n/a | -US$59m |
| Jun 30 2018 | n/a | n/a | -US$59m |
| Mar 31 2018 | n/a | n/a | -US$64m |
| Dec 31 2017 | US$4m | US$698k | -US$62m |
Compensación vs. Mercado: La compensación total de Asaf($USD2.28M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Asaf ha sido consistente con los resultados de la empresa en el último año.
CEO
Asaf Danziger (57 yo)
22.3yrs
Permanencia
US$1,521,026
Compensación
Mr. Asaf Danziger is a Director at Airway Therapeutics, Inc. since April 2020. He has been the Chief Executive Officer of Novocure Limited since 2002 and its Director since 2012 respectively and also serve...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 20.3yrs | US$1.43m | 0.51% $ 8.6m | |
| CEO & Director | 22.3yrs | US$1.52m | 0.013% $ 217.3k | |
| Chief Financial Officer | 3.7yrs | US$6.32m | 0.083% $ 1.4m | |
| Chief Operating Officer | 3.7yrs | US$5.97m | 0.17% $ 2.8m | |
| General Counsel | 2.1yrs | US$4.86m | 0.019% $ 312.5k | |
| Executive VP & President of Novocure Oncology | 3.7yrs | US$5.04m | 0.052% $ 863.0k | |
| Founder & CTO | 24.3yrs | US$282.51k | sin datos | |
| Chief Science Officer | 1.3yrs | sin datos | 0.0065% $ 108.8k | |
| VP of Investor Relations | no data | sin datos | sin datos | |
| Chief Human Resources Officer | less than a year | sin datos | sin datos | |
| Chief Innovation Officer | 1.3yrs | sin datos | 0.058% $ 960.9k | |
| Senior VP | no data | sin datos | sin datos |
3.7yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de NVCR se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Executive Chairman | 20.3yrs | US$1.43m | 0.51% $ 8.6m | |
| CEO & Director | 12.3yrs | US$1.52m | 0.013% $ 217.3k | |
| Independent Director | 5.8yrs | US$446.09k | 0.0024% $ 39.4k | |
| Independent Director | 6yrs | US$426.09k | 0.0085% $ 141.9k | |
| Independent Director | 3.3yrs | US$448.53k | 0.000070% $ 1.2k | |
| Independent Director | 12.6yrs | US$435.53k | 0.070% $ 1.2m | |
| Lead Independent Director | 18.3yrs | US$475.53k | 0.15% $ 2.5m | |
| Independent Director | 7yrs | US$446.09k | 0.015% $ 242.7k | |
| Independent Director | 1.2yrs | US$696.94k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$697.26k | 0% $ 0 |
6.5yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de NVCR se considera experimentada (6.4 años de antigüedad promedio).